Hundreds will benefit after the first targeted treatment for the most common form of bladder cancer was given the green light ...

Hundreds of patients are expected to benefit from the recommendation by the National Institute of Health and Care Excellence.

The first targeted treatment for the most common form of bladder cancer has been given the green light for NHS use. The ...

The oral drug – Johnson & Johnson's Balversa (erdafitinib) – will become an option for adults with metastatic or unresectable ...

The investigational therapy combines mRNA technology with immunotherapy to train the immune system to target cancer cells ...

Hundreds will benefit after the first targeted treatment for the most common form of bladder cancer was given the green light ...

Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration ...

Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary ...

Erdafitinib, also known as Balversa and made by Johnson & Johnson, is recommended in final draft guidance for adults with metastatic or unresectable FGFR-altered urothelial cancer who have previously ...

Bavencio as first-line maintenance was associated with long-term efficacy in advanced urothelial carcinoma regardless of ...

A new, error-corrected method for detecting cancer from blood samples is much more sensitive and accurate than prior methods and may be useful for monitoring disease status in patients following ...

The drug, recommended by NICE, works by blocking certain proteins to slow down or stop the growth of cancer cells ...